What changed from existing technology?
This study looked at how inflammation in the blood relates to depression in teenagers, comparing those who started having depression before age 13 with those who started at 13 or older.
This is the first study to compare serum inflammatory factors in adolescents with major depressive disorder based on the age of first onset.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
order (MDD) at various ages of first onset. Adolescent patients (13–18 years) with MDD who were hospitalized in the Fourth People’s Hospital of Hefei City bet
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings may help in understanding the biological mechanisms underlying early-onset depression and could inform targeted interventions for adolescents with a history of childhood trauma.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.